BACKGROUND AND PURPOSE: Recurrent malignant gliomas have a very poor prognosis. This trial aimed to evaluate the benefits of reirradiation in case of recurrent glioblastoma multiforme (GBM) using hypofractionated stereotactic radiotherapy (hFSRT) after primary high-dose percutaneous irradiation. PATIENTS AND METHODS: Between 1998 and 2008, 53 patients with recurrent GBM were treated by hFSRT based on CT and MR imaging. At the time of recurrence, a median total dose of 30 Gy (20-60 Gy) was delivered in median fractions of 3 Gy/day (2-5Gy). RESULTS: The reirradiation was well tolerated (no acute or late toxicity > grade 2), despite the relatively large median tumor volume (35.01 ml). Karnofsky Performance Score was the strongest predictor for survival after reirradiation (p = 0.0159). Tumor volume (p = 0.4690), patient age (p = 0.4301), second operation (p = 0.6930), and chemotherapy (p = 0.1466) at the time of reirradiation did not affect survival. After hFSRT, the median survival was 9 months, and the 1-year progression-free survival (PFS) amounted to 22%.The median overall survival from initial diagnosis was 27 months. 1-year survival from first diagnosis was 83%, 2-year survival 45%. The median time to progression from the end of initial irradiation to recurrence was 12 months. 1-year PFS before reirradiation was 40%. CONCLUSION: hFSRT as a secondary treatment of recurrent GBM is a feasible and effective treatment option. Only minor side effects were observed with prolonged life expectancy of 9 months.
BACKGROUND AND PURPOSE: Recurrent malignant gliomas have a very poor prognosis. This trial aimed to evaluate the benefits of reirradiation in case of recurrent glioblastoma multiforme (GBM) using hypofractionated stereotactic radiotherapy (hFSRT) after primary high-dose percutaneous irradiation. PATIENTS AND METHODS: Between 1998 and 2008, 53 patients with recurrent GBM were treated by hFSRT based on CT and MR imaging. At the time of recurrence, a median total dose of 30 Gy (20-60 Gy) was delivered in median fractions of 3 Gy/day (2-5Gy). RESULTS: The reirradiation was well tolerated (no acute or late toxicity > grade 2), despite the relatively large median tumor volume (35.01 ml). Karnofsky Performance Score was the strongest predictor for survival after reirradiation (p = 0.0159). Tumor volume (p = 0.4690), patient age (p = 0.4301), second operation (p = 0.6930), and chemotherapy (p = 0.1466) at the time of reirradiation did not affect survival. After hFSRT, the median survival was 9 months, and the 1-year progression-free survival (PFS) amounted to 22%.The median overall survival from initial diagnosis was 27 months. 1-year survival from first diagnosis was 83%, 2-year survival 45%. The median time to progression from the end of initial irradiation to recurrence was 12 months. 1-year PFS before reirradiation was 40%. CONCLUSION: hFSRT as a secondary treatment of recurrent GBM is a feasible and effective treatment option. Only minor side effects were observed with prolonged life expectancy of 9 months.
Authors: Stephanie E Combs; Sybille Gutwein; Daniela Schulz-Ertner; Michael van Kampen; Christoph Thilmann; Lutz Edler; Michael M Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2005-06 Impact factor: 3.621
Authors: Martin Henzel; Klaus Hamm; Markus W Gross; Gunnar Surber; Gabriele Kleinert; Thomas Failing; Helmut Sitter; Gerd Strassmann; Rita Engenhart-Cabillic Journal: Strahlenther Onkol Date: 2007-10 Impact factor: 3.621
Authors: Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje Journal: BMC Cancer Date: 2005-05-30 Impact factor: 4.430
Authors: Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller Journal: Strahlenther Onkol Date: 2010-11-29 Impact factor: 3.621
Authors: Joshua D Palmer; Joshua Siglin; Kosj Yamoah; Tu Dan; Colin E Champ; Voichita Bar-Ad; Maria Werner-Wasik; James J Evans; Lyndon Kim; Jon Glass; Christopher Farrell; David W Andrews; Wenyin Shi Journal: J Neurooncol Date: 2015-05-30 Impact factor: 4.130
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481